Risk for T2D Increased for Individuals With Late Chronotype
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 11, 2024 -- People with a late chronotype have an increased risk for type 2 diabetes (T2D) and have higher body mass index (BMI) and larger waist circumference, according to a study presented at the annual meeting of the European Association for the Study of Diabetes, held from Sept. 9 to 13 in Madrid.
Jeroen H.P. van der Velde, Ph.D., from Leiden University Medical Center in the Netherlands, and colleagues calculated the mid-point of sleep (MPS) and defined three chronotypes: late, intermediate, and early (MPS ≥4.00, 2.30 to 4.00, and <2.30) and examined their association with BMI, waist circumference, visceral fat, liver fat, and the risk for T2D in the Netherlands Epidemiology of Obesity study.
A total of 5,026 participants were analyzed in the study; 20 percent had a late chronotype. The researchers found that 225 participants were diagnosed with T2D during a median follow-up of 6.6 years. Participants with a late versus an intermediate chronotype had an increased risk for T2D (hazard ratio, 1.46). Those with a late chronotype also had 0.7 g/m2 higher BMI, 1.9 cm larger waist circumference, 7 cm2 more visceral fat, and 14 percent more liver fat.
"People with a late chronotype appear to be at greater risk of developing type 2 diabetes compared to those with intermediate chronotype, possibly because of higher body fat including more visceral fat and liver fat," van der Velde said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-12 08:59
Read more
- Improvement Seen in Some Features of PCOS With Weight Loss Interventions
- Work-Related Stress Linked to Lower Odds of Average, Optimal Heart Health
- Adult Hypertension Prevalence 47.7 Percent From August 2021 to August 2023
- Listeria Danger Spurs Nationwide Recall of Frozen Waffles
- Most Older Americans Don't Trust AI-Generated Health Info, Survey Finds
- Lithium Aspartate Not Effective for Neurologic Long COVID Fatigue
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions